Related Experiment Video
Updated: Sep 19, 2025

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health
Andres Rosende1, Cesar Romero2, Donald J DiPette3
1Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, District of Columbia, USA.
Insights
HEARTS 2.0 Phase 1 selected 45 interventions to improve cardiovascular and kidney care in primary settings. This update enhances the HEARTS Clinical Pathway for better hypertension, diabetes, and CKD management.
Area of Science:
- Public Health
- Cardiology
- Nephrology
Background:
- The HEARTS Initiative promotes cardiovascular disease (CVD) risk management in primary care.
- HEARTS 2.0 aims to unify fragmented guidelines for hypertension, diabetes, and chronic kidney disease (CKD) care.
- This study focuses on Phase 1: updating the HEARTS Clinical Pathway.
Purpose of the Study:
- To identify and select evidence-based interventions for Phase 1 of HEARTS 2.0.
- To enhance the existing HEARTS Clinical Pathway for integrated cardiovascular-kidney-metabolic care.
- To improve hypertension, diabetes, and CKD management in primary care settings.
Main Methods:
- Defined project scope, objectives, and methodology.
- International experts proposed interventions for the HEARTS Clinical Pathway.
- Used the RAND/UCLA Appropriateness Method for expert appraisal of interventions.
Main Results:
- Selected 45 unique interventions to enhance the HEARTS Clinical Pathway.
- Interventions include community screening, risk factor management, and updated treatment thresholds.
- Included SGLT2 inhibitors and expanded roles for non-physician health workers.
Conclusions:
- HEARTS 2.0 Phase 1 provides key interventions for integrated cardiovascular-kidney-metabolic care.
- The updated pathway will optimize resources and reduce care fragmentation.
- Aims to improve care delivery, advance health equity, and combat leading causes of death.
Background:
HEARTS in the Americas is the regional adaptation of the WHO Global HEARTS Initiative, aimed at helping countries enhance hypertension and cardiovascular disease (CVD) risk management in primary care settings. Its core implementation tool, the HEARTS Clinical Pathway, has been adopted by 28 countries. To improve the care of hypertension, diabetes, and chronic kidney disease (CKD), HEARTS 2.0 was developed as a three-phase process to integrate evidence-based interventions into a unified care pathway, ensuring consistency across fragmented guidelines. This paper focuses on Phase 1, highlighting targeted interventions to improve and update the HEARTS Clinical Pathway.
Methods:
First, the coordinating group defined the project's scope, objectives, principles, methodological framework, and tools. Second, international experts from different disciplines proposed interventions to enhance the HEARTS Clinical Pathway. Third, the coordinating group harmonized these proposals into unique interventions. Fourth, experts appraised the appropriateness of the proposed interventions on a 1-to-9 scale using the adapted RAND/UCLA Appropriateness Method. Finally, interventions with a median score above 6 were deemed appropriate and selected as candidates to enhance the HEARTS Clinical Pathway.
Results:
Building on the existing HEARTS Clinical Pathway, 45 unique interventions were selected, including community-based screening, early detection and management of risk factors, lower blood pressure thresholds for diagnosing hypertension in high-CVD-risk patients, reinforcement of single-pill combination therapy, inclusion of sodium-glucose cotransporter-2 inhibitors for patients with diabetes, CKD, or heart failure, expanded roles for non-physician health workers in team-based care, and strengthened clinical documentation, monitoring, and evaluation.
Conclusion:
HEARTS 2.0 Phase 1 identifies key interventions to integrate and improve hypertension and cardiovascular-kidney-metabolic care within primary care, enabling their seamless incorporation into a unified and effective clinical pathway. This process will inform an update to the HEARTS Clinical Pathway, optimizing resources, reducing care fragmentation, improving care delivery, and advancing health equity, thereby supporting global efforts to combat the leading causes of death and disability.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Hypertension V: Nursing Management
Cardiomyopathy V: Interprofessional Care
Chronic Kidney Disease I: Introduction
Hypertension I: Introduction

